Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction (ROTAS)
Primary Purpose
Aortic Valve Stenosis
Status
Terminated
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
aortic valve replacement
strict clinical surveillance
Sponsored by
About this trial
This is an interventional treatment trial for Aortic Valve Stenosis focused on measuring severe aortic valve stenosis, low gradient, preserved left ventricular ejection fraction, symptomatic patients
Eligibility Criteria
Inclusion Criteria:
- Age >18 years
- Symptomatic and severe AS defined by an effective AVA ≤1 cm² and indexed AVA ≤0.6 cm2/m2
- LVEF ≥50%
- MAG <40 mm Hg (measure confirmed by the multi-window continuous-wave Doppler interrogation and use of Pedoff probe)
- Confirmation of the presence of severe AS at DSE and MDCT aortic calcium score
- Feasibility of AVR by surgery or TAVR according to the "heart team"
- Signature of an informed consent
Exclusion Criteria:
- Uncontrolled atrial of ventricular arrhythmias
- Patient having a life expectancy <1 year, independently from their aortic pathology
- Coronary artery disease necessitating a percutaneous or surgical revascularisation
- Presence of a concomitant valve disease needing surgical treatment
- Patient who are included in another research protocol
- Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman and minor)
Sites / Locations
- CHU Liège
- CHU Amiens - Picardie
- CHU Angers
- CHU Brest - Hôpital La Cavale Blanche
- APHP - CHU Henri Mondor
- CHU Dijon - Hôpital François Mitterrand
- CHU Lille
- CH Bretagne Sud
- APHM - Hôpital La Timone
- Clinique du Millénaire
- CHU Nantes
- CHU Rennes
- CH Saint-Brieuc
- Centre Cardiologique du Nord
- CHU Toulouse - Hôpital Rangueil
- CHU Tours - Hôpital Trousseau
- CHU Nancy
- CH Bretagne Atlantique - Site de Vannes
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
aortic valve replacement
strict clinical surveillance
Arm Description
Outcomes
Primary Outcome Measures
time from randomization to first occurrence of any of the components of the composite outcome (adjudicated): all-cause mortality or cardiovascular related hospitalization
Secondary Outcome Measures
rate of all-cause mortality
rate of cardiovascular mortality
rate of cardiovascular related hospitalization
rate of cerebrovascular events
walking distance
6-minute walking test
NT-proBNP plasma levels
quality of life score
test EQ-5D
Full Information
NCT ID
NCT03667365
First Posted
September 10, 2018
Last Updated
February 27, 2023
Sponsor
Rennes University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03667365
Brief Title
Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction
Acronym
ROTAS
Official Title
Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Terminated
Why Stopped
new US guidelines
Study Start Date
March 19, 2019 (Actual)
Primary Completion Date
November 16, 2021 (Actual)
Study Completion Date
November 16, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rennes University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
According to current European Recommendations on valvular heart disease (VHD), "classical" severe aortic stenosis (AS) is defined by an aortic valve area (AVA) ≤1 cm2 and indexed AVA ≤0.6 cm2/m2, a mean aortic pressure gradient (MAG) >40 mmHg, and a maximal aortic velocity >4 m/sec.
Aortic valve replacement (AVR) is recommended (class I indication) in patients with "classical" severe AS who have any symptoms related to aortic valve disease.
In 2007, Hachicha et al. described a particular pattern of severe AS, characterized by an AVA ≤0.6 cm2/m2, low mean pressure aortic gradient (MAG <40 mmHg), despite the presence of a preserved left ventricular ejection fraction (LVEF ≥50%). This pattern of AS is encountered in nearly 15-25 % of patients who have severe AS. Typically, these patients are elderly subjects, with several comorbidities, a small left ventricular (LV) cavity with pronounced LV concentric remodeling and a restrictive physiology, leading to a decrease in LV stroke volume despite a preserved LVEF. The diagnosis and management of patients with low gradient severe AS and preserved LVEF are often challenging because:
the presence of a "true" severe aortic stenosis should be carefully confirmed by a multi-modality imaging approach;
the best therapeutic management (AVR versus conservative strategy) of symptomatic patients with low gradient severe AS and preserved LVEF is not clearly established.
In very recently updated European guidelines on the management of VHD, symptomatic patients with low gradient and low flow severe AS and preserved LVEF have only a class IIa-level C indication for AVR. No specific indications are given for the management of symptomatic patients with low gradient and normal flow severe AS. This lack of indications is clearly attributed to a gap in knowledge which requires further investigations to be filled up.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Stenosis
Keywords
severe aortic valve stenosis, low gradient, preserved left ventricular ejection fraction, symptomatic patients
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
52 (Actual)
8. Arms, Groups, and Interventions
Arm Title
aortic valve replacement
Arm Type
Experimental
Arm Title
strict clinical surveillance
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
aortic valve replacement
Intervention Description
aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
Intervention Type
Other
Intervention Name(s)
strict clinical surveillance
Intervention Description
strict clinical surveillance strategy
Primary Outcome Measure Information:
Title
time from randomization to first occurrence of any of the components of the composite outcome (adjudicated): all-cause mortality or cardiovascular related hospitalization
Time Frame
during 2 years follow-up
Secondary Outcome Measure Information:
Title
rate of all-cause mortality
Time Frame
2 years
Title
rate of cardiovascular mortality
Time Frame
2 years
Title
rate of cardiovascular related hospitalization
Time Frame
2 years
Title
rate of cerebrovascular events
Time Frame
2 years
Title
walking distance
Description
6-minute walking test
Time Frame
6, 12, 18 and 24 months
Title
NT-proBNP plasma levels
Time Frame
6, 12, 18 and 24 months
Title
quality of life score
Description
test EQ-5D
Time Frame
6, 12, 18 and 24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age >18 years
Symptomatic and severe AS defined by an effective AVA ≤1 cm² and indexed AVA ≤0.6 cm2/m2
LVEF ≥50%
MAG <40 mm Hg (measure confirmed by the multi-window continuous-wave Doppler interrogation and use of Pedoff probe)
Confirmation of the presence of severe AS at DSE and MDCT aortic calcium score
Feasibility of AVR by surgery or TAVR according to the "heart team"
Signature of an informed consent
Exclusion Criteria:
Uncontrolled atrial of ventricular arrhythmias
Patient having a life expectancy <1 year, independently from their aortic pathology
Coronary artery disease necessitating a percutaneous or surgical revascularisation
Presence of a concomitant valve disease needing surgical treatment
Patient who are included in another research protocol
Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman and minor)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elena EG Galli, MD
Organizational Affiliation
CHU Rennes
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Erwan ED Donal, PhD
Organizational Affiliation
CHU Rennes
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Liège
City
Liège
Country
Belgium
Facility Name
CHU Amiens - Picardie
City
Amiens
Country
France
Facility Name
CHU Angers
City
Angers
Country
France
Facility Name
CHU Brest - Hôpital La Cavale Blanche
City
Brest
Country
France
Facility Name
APHP - CHU Henri Mondor
City
Créteil
Country
France
Facility Name
CHU Dijon - Hôpital François Mitterrand
City
Dijon
Country
France
Facility Name
CHU Lille
City
Lille
Country
France
Facility Name
CH Bretagne Sud
City
Lorient
Country
France
Facility Name
APHM - Hôpital La Timone
City
Marseille
Country
France
Facility Name
Clinique du Millénaire
City
Montpellier
Country
France
Facility Name
CHU Nantes
City
Nantes
Country
France
Facility Name
CHU Rennes
City
Rennes
ZIP/Postal Code
35000
Country
France
Facility Name
CH Saint-Brieuc
City
Saint-Brieuc
Country
France
Facility Name
Centre Cardiologique du Nord
City
Saint-Denis
Country
France
Facility Name
CHU Toulouse - Hôpital Rangueil
City
Toulouse
Country
France
Facility Name
CHU Tours - Hôpital Trousseau
City
Tours
Country
France
Facility Name
CHU Nancy
City
Vandœuvre-lès-Nancy
Country
France
Facility Name
CH Bretagne Atlantique - Site de Vannes
City
Vannes
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction
We'll reach out to this number within 24 hrs